References
- Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–1020.
- Siddiqi OK, Ruberg RL. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28:10–21.
- Ruberg FL, Mauer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;64:222–228.
- Benson MD, Teague SD, Kovacs R, et al. Rate of progression of transthyretin amyloidosis. Am J Cardiol. 2011;108:285–289.
- Benson MD, Dasgupta NR, Rissing SM, et al. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid. 2017;24:219–225.